Background: Epidermolysis bullosa simplex (EBS) is a rare genetic, blistering skin disease for which there is no cure. Treatments that address the pathophysiology of EBS are needed.
Generalized severe epidermolysis bullosa simplex (EBS-gen/sev) (formerly EBS Dowling-Meara) is a rare, genetic disease that primarily affects the skin and mucous membranes. Its prevalence in the United States is approximately 8 per million, at an incidence of 19 per million live births. 1, 2 Currently, treatment is limited to the alleviation of secondary manifestations and conventional wound care. 3 The development of a 1% diacerein cream for the topical treatment of EBSgen/sev is based on the underlying pathophysiologic mechanism. EBS-gen/ sev is characterized by autosomal dominant keratin 5 gene (KRT5) and keratin 14 gene (KRT14) mutations, which lead to conformational changes in the intermediate filament network (IFN) of basal keratinocytes. 4 Consequently, the IFN disintegrates even under low mechanical stress and forms keratin aggregates in the cytoplasm. In the final manifestation, cytolysis of basal keratinocytes phenotypically presents as blisters and erosions of the skin. 5 In vitro studies have suggested a positive feedback loop in which keratin aggregates induce an increased level of maturation and secretion of interleukin 1b (IL-1b), which in an autocrine mode of action activates the Jun amino-terminal kinase stress pathway; this, in turn, promotes the expression of KRT14 and an aggravation of the cellular state. In vitro experiments showed that diacerein is able to disrupt this vicious cycle, resulting in stabilization of the IFN and consequently the basal keratinocytes. 6 The positive effects of diacerein in downregulating the IL-1b signaling cascade noted in vitro were the basis for a pilot clinical study using this small molecule to improve phenotypic manifestations of EBS-gen/sev. 7 Accordingly, the number of blisters was reduced significantly as early as 2 weeks after the start of active treatment in an open-label phase and remained significantly below the initial level even during randomized controlled, active treatment withdrawal. These findings indicated a long-term and clinically relevant effect of diacerein and provided the rationale for the present randomized, vehicle-controlled, phase 2/3 clinical trial.
METHODS

Study design
The study was a randomized, vehicle-controlled, double-blind, sample sizeeplanned trial. The 15 patients who were initially enrolled into the trial were randomly assigned to either the placebo or the diacerein group in a 7:8 ratio. In the end, considering dropouts and their replacement, the final randomization ratio was 10:7, with a 7:8 ratio of patients who concluded the trial per protocol. Treatment for 4 weeks was followed by a 3-month follow-up and a mean washout period of 5.6 months (standard deviation, 1.7). Thereafter, a crossover led into the second treatment episode (TREP), resulting in an 8:7 distribution between groups.
Visits were performed at the start of the trial (T0), after 2 weeks (T2), 4 weeks (T4), and after the follow-up (T7). The aim of the visits was to monitor the recurrence of blisters in the treated area and to document duration of the treatment effect and potential adverse events (AEs). For TREP2, groups were crossed over to the other treatment (ie, all patients who originally received placebo then received diacerein and vice versa). Time points of the visits (T8, T10, T12, T15) corresponded to the respective time points in trial period (TP) 1 (Fig 1) . Blisters in the treated body surface areas (BSAs) were counted by a study nurse at each visit, and photographs for final evaluations were taken. The design and methodology of the trial were reviewed and approved by the local ethics committee of the province of Salzburg, Austria (institutional review board No. 415-E/1619/23-2014; date, July 4, 2013).
Study medication
The investigational medicinal product (IMP) consisted of 1% diacerein as the active ingredient (Duke Chem SA, Barcelona, Spain) 8 in an Ultraphil cream base (Bayer, Vienna, Austria). Because diacerein gives a yellowish color to the cream, the placebo consisted of Ultraphil with 0.005% tartrazine to make the creams visually indistinguishable. Production was performed under Good Manufacturing Practice conditions. The IMP and comparator were applied once daily for 4 weeks to 3% of the total BSA presenting with blisters at the time of start of treatment. The amount of product applied was equivalent to 3 patient-sized fingertip units spread onto 1 or more defined skin areas.
Study participants
In total, 17 patients in whom EBS-gen/sev was diagnosed by mutation analysis (Table I 9-15 ) gave consent to participate in the study. Exclusion criteria were other subtypes of EB, simultaneous participation in another clinical study, and known or suspected intolerance to diacerein, auxiliaries of the IMP (especially tartrazine), or substances with similar structure. Pregnant or lactating females were not included. Additional reasons for exclusion were the presence of other diseases considered relevant and severe hepatic impairment. Written informed consent by proxy was obtained for all participants.
End points
Primary end point. The primary end point was the proportion of patients with more than a 40% reduction from baseline in number of blisters within the treated areas through the end of each 4-week TREP.
Secondary end point. As a secondary end point the proportion of patients with recurrence of initial blister numbers plus or minus 10% at the end of both TPs was assessed. An additional secondary end point was the proportion of patients with a reduction of blister numbers by more than 40% on the treated BSA from baseline to the end of the follow-up period.
Additional assessments. Pruritus and pain were assessed by the study nurse at each visit by using a visual analogue scale, according to which 0 indicated no pain/pruritus and 10 indicated worst pain/pruritus. Quality of life was assessed with a questionnaire. 7 Patients were asked to complete the questionnaire at the T0/T7 and the T8/T15 visits (Supplemental Figs 1 and 2; available at: http:// www.jaad.org).
Statistical methods
Randomization and blinding. From the 17 patients enrolled, 15 were randomized at T0 (7 of whom were assigned to the diacerein group and 8 of whom were assigned to the control group). For randomization, random numbers computergenerated on the basis of the random sorting method were used. 16 Blinding based on the 4-eyes principle was done after randomization. Two patients were recruited in a second recruitment round to replace dropouts.
Data collection, sample size planning, and evaluation. Sample size planning was based on the results from a pilot study, in which a significant difference of means of 9.3 (standard deviation, 3.4) was calculated. The empirical correlation was r = 0.96. A maximum 10% dropout rate was expected. On the basis of a 2-sided dependent Student t test, a type I error of 5%, and a sample size of 15, a power of at least 80% was achieved to detect an effect of 9.3 or more (Supplemental Method 1; available at http://www.jaad.org). 21 were used to analyze data (Supplemental Method 2; available at http://www. jaad.org).
Data acquisition
For final evaluations, blisters were counted by 3 independent, blinded raters, on the basis of photographs taken at each visit. Raters were specifically trained in blister classification, and they agreed on a final consensus. Blisters were classified before counting (Fig 2) . Consensus counts were transferred to an Excel file and subjected to statistical evaluations.
RESULTS
Patients and treatment adherence
In total, 17 patients were screened and included in the study. In the initial screening round, 15 patients were enrolled, 1 of whom in the placebo group dropped out of the trial after the first visit for personal reasons. This patient was replaced by a new patient, as envisaged in the study protocol. A second patient in the placebo group also interrupted the treatment after the first visit of TREP1 because of an influenza infection but participated in TP2. For this patient, a new patient was recruited to participate in the study for 1 TP only (Fig 3) . Both dropout events were classified as not study related.
Baseline characteristics
The average patient treatment area was 291 cm 2 . Areas were chosen with the patient's consent, provided that blisters were present at the beginning of the TPs (T0/T8). The total number of blisters for all patients at T0/T8 was 199, with the blisters covering an overall skin surface area of 9301 cm 2 . In the placebo group, 102 blisters covering 5045 cm 2 were counted at T0/T8, and 97 blisters covering 4257 cm 2 were counted in the diacerein group (Table II) In all, 39 defined skin areas were treated; they were located on the arms or armpits (15) , legs (12), trunk (5), buttocks (4), or feet (3). The wide distribution of the different skin areas is typical for areas that are most subject to mechanical friction (Table III) .
Primary end point: reduction in blister number by more than 40%
Efficacy was evaluated on the basis of blister counts at each time point per group (Supplemental Fig 3; available at: http://www.jaad.org).
Clinically, blisters healed without scarring or visible potential side effects (Fig 4, A) . In TREP1, 86% of patients receiving diacerein and 14% of the placebo-treated patients achieved a reduction in blister number of more than 40%. At the end of follow-up, all diacerein-treated patients, as compared with 57% of all placebo patients, showed a reduction of more than 40% (Fig 4, B and D) . In TREP2, 37.5% of all diacerein-treated patients and 17% of all placebo-treated patients achieved a reduction in blister number of more than 40%. At the end of follow-up, 75% of all diacerein-treated patients, as compared with 17% of all placebotreated patients, achieved this outcome (Fig 4, C  and D) .
Additionally, the mean differences in absolute blister numbers between the start and the end of the intervention, as well as between the start and the end Generalized severe epidermolysis bullosa simplex. Overview of study design, patient screening, and enrolment. The trial was conducted over 2 successive trial periods (TPs), with a crossover of groups after period 1 and an extensive washout. In TP2, a placebo group and a diacerein group received medication for 4 weeks and were followed up for 3 months. Time points of study nurse visits (V) and data collection (T) are indicated. J AM ACAD DERMATOL VOLUME 78, NUMBER 5
Fig 2.
Generalized severe epidermolysis bullosa simplex. Blister classification. Single blisters were defined as a count of 1. Blister nests derived from 1 healing blister were defined as a count of 1. Redness without convexes was not counted. Only time points for which good quality photographs were available (good resolution, clear visualization of blisters) were included in the final evaluations. Blisters were counted in the context of the whole treatment to distinguish between active and healing blisters. Table I . AE, Adverse event.
J AM ACAD DERMATOL of the follow-up, were significantly different for the diacerein group but not for the placebo group (Fig 5) . There was also a significant decrease in blister number in the diacerein group from the end of the TREP to the end of the follow-up. Finally, blister numbers were significantly different between the diacerein-and placebo-treated groups after the TREPs and after the follow-up (Fig 5, C ) .
Secondary end point: recurrence of initial blister number by plus or minus 10% Whereas there was no significant difference between placebo and diacerein in TP1, in year 2 significantly more patients from the placebo group than from the diacerein group reached 90% or more of their initial blister number at the end of the 3-month follow-up. Also after TP1, however, the mean percentage of blisters at the end of the follow-up was much lower for diacerein (10 In total, only 1 patient in the diacerein group reached 90% or more of the initial blister number at the end of the 3-month follow-up, as opposed to 4 patients in the placebo group. These results point toward long-term effects of the treatment, as also observed in the pilot study (Fig 6) .
AEs
None of the 13 reported AEs was classified as study related or led to a dose reduction, adisruption, or termination of study participation. Also, none of the AEs reported were within the treated area (Table IV) .
DISCUSSION
Diacerein specifically targets IL-1b, a key player in the pathophysiology of EBS-gen/sev, as identified in previous studies. 5, 22 In this study we confirmed superiority of a 1% diacerein cream over placebo in reducing the numbers of blister in patients with EBSgen/sev. A significant response was observed within the 4 weeks of treatment, with good persistence throughout the 3-month follow-up.
Designing a clinical trial for a patient population affected by a rare disease is demanding, given that participation in the trial must be logistically reasonable for the patients, and the trial must also have the potential to generate significant data despite the low patient numbers. It is possibly for this reason that there is hardly any literature on randomized controlled trials in EB. [23] [24] [25] [26] [27] [28] Still, there is a pressing need for treatments that address the underlying pathophysiology of this blistering disease and can reduce blister numbers with an acceptable side effect profile. Currently, however, progress has been made only in the field of ex vivo gene therapy for distinct subtypes of EB (junctional and dystrophic). [29] [30] [31] For dominantly inherited EBS, this approach is not currently applicable.
In designing our trial, we considered aspects that were important for achieving a high-quality outcome. First, we considered age and chose an Skin areas to be treated, accounting for 3% of the total body surface area, were chosen with the patient's consent, provided that blisters were present at T0 and T8. In only 1 patient, who was assigned to placebo in treatment period 1, was the same skin area treated in both treatment periods. EBS-gen/sev, Generalized severe epidermolysis bullosa simplex.
upper limit of 19 years, as patients in this age range are most heavily affected. Second, we chose a crossover design to reduce the influence of confounding covariates, as each crossover patient serves as his or her own control, and to minimize imbalances between groups in this small patient population. Nevertheless, the 17 patients enrolled were recruited from 4 countries. For data acquisition, we believed that counting the blisters was the most reliable and patient-relevant way of monitoring the effect of a diacerein treatment. This method would also compensate for a lack of photographic technology that could ensure absolutely representative pictures for calculating blister areas. Finally, the Absolute blister numbers between the start and end of the intervention, as well as between the start and end of follow-up, were significantly different for the diacerein group but not for the placebo group. C, Blister numbers were significantly different between the diacerein and placebo groups at 4 weeks and 4 months after treatment initiation. The mean number of blisters at the beginning of each trial period was 6.2 for both the diacerein-and the placebo-treated patients. The mean difference between groups was 2.5 blisters after 4 weeks of treatment and 3.4 blisters after the follow-up. Means with 95% CIs are shown; P values are 2 sided.
J AM ACAD DERMATOL VOLUME 78, NUMBER 5 counted blister numbers represented a consensus among the 3 independent raters who based their counts on the photographs taken at each visit and provided the basis for outcome evaluation. The results demonstrated that diacerein significantly reduced blister numbers in patients with EBSgen/sev. A more than 40% reduction of blister numbers, which is regarded to be a clinically meaningful outcome, was reached in 60% of patients in the diacerein group. We assume that the minor reductions in the placebo group are due to the regular and intensive care during the study period, which is often neglected in everyday life, as well as to well-described fluctuations in disease severity 32 and presumably also to a placebo effect, which is seen in a majority of randomized controlled clinical trials. 33, 34 As observed in the pilot study, 8 a carryover effect of diacerein was apparent. In this pilot study, patients achieved a reduction of blisters by more than 70% upon application of 1% diacerein cream for 6 weeks. However, blisters did not recur during a 6-week placebo-controlled randomized withdrawal. This indication of the potential for a long-term effect of the treatment was again observed in this trial, in which only 1 patient in the diacerein group (12.5%) versus 67% of patients in the placebo group had recurrence to their initial numbers of blisters at the end of the follow-up. Regarding absolute blister numbers, there was a continuous and significant reduction in blister numbers over the whole study period in the diacerein group only. A further statistically significant decrease in blister numbers following treatment, which we noted, underlines the potential long-term effect of the IMP.
Interestingly, the impact of pain and pruritus in this disease rated the highest scores for differences between diacerein and placebo in the patients' quality of life assessment, but these scores did not correspond with the nurse-recorded scores on the analogue scale. This difference may be accounted for by the low percentage of BSA treated, individual differences in pain sensation (reflected by widely differing scores at T0/T8), and difficulty in separating the perception of pain and pruritus in the treated BSA from that in the rest of the body.
Various medicines were additionally administered during the trial, including painkillers and antihistamines. In no case were the symptoms requiring medication classified as study related or as affecting the skin area treated in the trial. Percentage of patients for period 2 reaching at least 90% of the initial blister number at the end of the follow-up period. *Indicates statistically significant differences between the respective groups. Means with 95% confidence intervals (CIs) are shown; the Barnard exact test, *P values are 1 sided; y P value is 2 sided. No serious adverse events were reported, and none of them were classified as related to the study medication or affected the area of treatment. A slight yellowish coloring of the skin disappeared approximately 2 weeks after treatment, indicating absorption of the cream by the skin. EBS-gen/sev, Generalized severe epidermolysis bullosa simplex.
As the awareness of rare diseases continues to increase, it is becoming clear that for many of them, no cure is currently available. In this study, we have shown the excellent tolerability and the superiority of diacerein over placebo for EBS, a rare skin disease for which diacerein is the first targeted treatment.
Statistical evaluation of quality of life questionnaires was done as contract labor by the Institute of Mathematics, Paris-Lodron-University of Salzburg, which specializes in the evaluation of questionnaires. p-value communications provided editorial support.
SUPPLEMENTAL METHODS 1: SAMPLE SIZE PLANNING
Sample size calculation in the trial protocol was done for a reduction of the number of blisters in all patients after 4 weeks of treatment. The clinically relevant difference was a reduction of 40% between the means of the number of blisters before and after treatment. However, because the wording of this end point was interpretated and discussed by different authorities and consultants as the number of patients who achieved a greater than 40% reduction after 4 weeks of treatment, evaluations of the trial outcome were adapted accondingly. Still, for both interpretations, the end point was achieved.
To verify that the sample size calculation was also appropriate in the redefinition, however, a power analysis was done as follows: in the pilot study 4 of 4 subjects (100%) under treatment showed a reduction of blisters greater than 40% after 4 weeks of intervention. S1 However, this pilot study started with a 6-week open treatment period only, and no independent control group was available. On the basis of our clinical experience, we assumed that less than 10% of patients receiving placebo would meet the primary end point. Although we observed that 100% of all subjects met the end point in the pilot study, we decided to reduce our expectations and assumed that only 80% under treatment would meet the end point. This was done because of the small sample size in the pilot study and the lack of placebo data. By using the Barnard test for superiority, we achieved a power of 87% in the pilot study under these assumptions, with a type I error of 5% and a sample size of 7 per group (ie, 14 patients in total). Further assuming a dropout rate of less than 10%, we ended up with 15 subjects.
In the final phase II/III study, we actually observed a blister reduction greater than 40% in 14% of all subjects in the control group and in 86% in the treatment group at T4. The Barnard test for superiority based on Monte Carlo methods detected a significant difference in the primary end point between verum and placebo (P = .007) in the first year (86% vs 17%), but not in the second year (P = .32 [37.5% vs 17%]). The comparison in the first year achieves a power of 89%, which is almost identical to the initially estimated 87%.
SUPPLEMENTAL METHOD 2: DATA EVALUATION
Data were checked for consistency in terms of typing errors, and ranges were inspected for validity. Because the data did not follow a normal distribution, specific distributions were used to model the underlying distributions in the generalized estimating equation (GEE) models: the Poisson distribution was used for the number of blisters, and the Tweedie distribution was used to model blisters expressed as a percentage, whereby the number of blisters of each patient was normalized to 100% at times T0 and T8. The patient identification number was the subject factor. Group, time, and treatment period were treated as fixed factors, with group and time treated as main and interaction factors. Treatment period was treated as main factor only. The robust estimator for the covariance matrix was used. In the case of significance of the treatment period, the results were treated separately for treatment period 1 and treatment period 2. Otherwise, the results of the first and second treatment periods were analyzed together. The primary end point, as well as 90% recovery event, were also modeled by GEE models, with the binomial distribution used as the underlying distribution. In both cases, however, the corresponding Hesse matrices were singular, and as a result, it was not possible to apply the GEE model. Therefore, the Barnard test for superiority was applied for each treatment period separately. Because of the small sample sizes, Monte Carlo methods were used for the Barnard test of superiority to yield exact P values instead of asymptotically derived P values only.
Primary and secondary end point
For evaluation of the primary end point, those patients who had complete data for a respective treatment period were included, as a responder was defined as a patient who showed a reduction of more than 40% within 4 weeks of treatment. Patients were considered to have completed a treatment period when all data for all time points within that period were available. If data were incomplete (ie, single time points were missing), the data from the respective treatment phase was excluded. When this criterion was applied, 15 patients had complete data for the diacerein treatment periods, as did 13 for the placebo treatments ( Supplemental Fig 3, B and C and Supplemental Fig 4) .
Evaluation of reduction of blister numbers
For calculating the average reduction of blister numbers, only those patients who had complete data for both treatment periods were included in the evaluation. In this manner, the strength of the crossover trial design, which is that there are diacerein and placebo data available for all patients and thus every patient serves as his own control, is reflected. Here, only the 13 patients who had complete data for both diacerein and placebo treatment phases were included in the analyses (Supplemental Fig 3, D and Supplemental Fig 4) . Table showing the number of patients is included in the respective evaluations.
J AM ACAD DERMATOL VOLUME 78, NUMBER 5 Supplemental Fig 1. Assessment of pruritus and pain. Pain (A) and pruritus (B) were assessed by the study nurse at each visit by using a visual analogue scale with continuous numbers from 0 to 10, where 0 indicated no pain/pruritus and 10 indicated significant pain/ pruritus. Pruritus and pain, which were recorded at each visit by the study nurse, showed no significant differences over time or between groups. Means and 95% confidence intervals are given. The low percentage of body surface area treated, individual differences in pain sensation (which resulted in widely differing scores at the beginning of the treatment), and difficulty in separating the perception of pain and pruritus in the treated body surface area from that in the rest of the body are the reason for this outcome. Interestingly, the question on the quality of life questionnaire asking about pruritus and pain had a significant outcome, still indicating an impact of the treatment on the sensation of pain and pruritus (see Supplemental Fig 2) .
Supplemental Fig 2.
Assessment of quality of life. Quality of life was assessed by using the same questionnaire as utilized in the pilot study. Patients were asked to complete the 8 questions of the questionnaire at the T0/T7 and the T8/T15 visits (A). Analysis of quality of life assessments was performed for patients who completed both treatment periods. For question 1, on pruritus and pain (''Has your skin been itching recently or have you had pain?''), a positive treatment effect was demonstrated that was stronger for diacerein than for placebo. For the majority of all other questions, the trend was similar, although it was not strong enough to reject the null hypothesis (ie, no positive effect of the treatment). Calculation of the score distribution before and after the treatment showed no significant change in the score level for the placebo group for any of the questions, whereas for the diacerein group, there was a significant change in the score level for the first question, on overall pain and pruritus (B and C). Quality of life data were analyzed by using 2 different testing approaches based on relative effects (a nonparametric Behrens-Fisher situation S2 ): score distribution before and after the treatment and score change distributions. Interestingly, the impact of pain and pruritus in this disease rated the highest scores in the patients' quality of life assessment, but these scores did not correspond to the nurse-recorded scores on the analogue scale. We assume that this difference may be accounted for by the low percentage of body surface area treated, individual differences in pain sensation (which resulted in widely differing scores at the beginning of the treatment), and difficulty in separating the perception of pain and pruritus in the treated body surface area from that in the rest of the body.
J AM ACAD DERMATOL VOLUME 78, NUMBER 5 Supplemental Fig 3. Generalized severe epidermolysis bullosa simplex. Clinical pictures of treated body surface areas of patients from the diacerein group, representing different response rates are shown. A, Patients with blister numbers reduced by more than 60% from start of treatment. B and C, Representative pictures of patients with reduction in blister numbers by 40% to 60% and less than 40% (nonresponders), respectively. Only patients from the diacerein group are shown.
Supplemental Fig 4.
Generalized severe epidermolysis bullosa simplex. Clinical pictures of treated body surface areas of patients with a reduction in blister numbers greater than 40% only after the follow-up. Photographs of 2 of the 6 patients from the diacerein group meeting this criteria are shown. Neither of the patients had reached greater than 40% reduction in blister numbers after the intervention phase.
J AM ACAD DERMATOL VOLUME 78, NUMBER 5 Supplemental Different data sets were analyzed for each of the respective end points (described later). When the outcome of each treatment (diacerein vs placebo) for the entire study period was compared, only data sets that were complete for both treatment periods were included in the evaluation. As such, the advantage of crossover designs, which is the reduction of confounding covariances, comes into effect. When the outcome after each treatment period was analyzed separately but a difference between the start and the end of the treatment period and/ or the follow-up was analyzed, completeness of data for the respective treatment period was a requirement. *These numbers include overall numbers of randomized patients. Note that both dropouts were allocated in the placebo group.
